Year Founded
2020
Ownership
Private
Employees
~50
Stage
Phase 1
Modalities
Antibody-based immunotherapyBispecific antibody

DynamiCure General Information

Currently conducting Phase 1 trial of DCBY02 (NCT05496595) in advanced solid tumors. Second candidate DCSZ11 planned for clinical development.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Waltham, Massachusetts
United States

Drug Pipeline

DCBY02
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to DynamiCure's pipeline data

Book a demo

Key Partnerships

OliX Pharmaceuticals, Yale University, University of Colorado

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

DynamiCure Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view DynamiCure's complete valuation and funding history, request access »